+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Short duration treatment in genotype 1 chronic hepatitis C patients with rapid virologic response to pegylated interferon plus ribavirin



Short duration treatment in genotype 1 chronic hepatitis C patients with rapid virologic response to pegylated interferon plus ribavirin



Biomedicine and PharmacoTherapy 65(4): 303-306



In patients with chronic hepatitis C, rapid HCV-RNA clearance under treatment might allow shorter treatment duration without modifying the sustained virological response (SVR) rate. This study evaluated the impact of rapid virological response (RVR) in HCV genotype 1b infection management. In an open-label trial, 180 patients received standard doses of peginterferon alfa-2a plus ribavirin. Those with undetectable serum HCV-RNA at week 6 (RVR) received 24-week short-course treatment; patients with undetectable HCV-RNA at week 12 (early responders [ER]) received 48-week "standard of care" treatment; patients with positive HCV-RNA at week 12 (non-responders [NR]) stopped the treatment. Study end-point was to determine SVR rate at week 24. The following responses were observed: 24% RVR, 44% ER, 32% NR. Among RVR subjects, HCV-RNA baseline levels and age were significantly lower (P=0.038 and 0.035 respectively) than in non-RVR patients. At follow-up, 91% of RVR and 33% of ER patients achieved SVR. Among those with RVR, patients experiencing post-therapy relapse were older than those who achieved a SVR (P=0.028). Chronic HCV-1b patients, achieving RVR with a 24-week treatment regimen, attained excellent SVR rates. In a cost-effective therapeutic approach, all HCV-1b patients eligible for therapy may have a short duration therapy on the basis of RVR.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 055757997

Download citation: RISBibTeXText

PMID: 21723079

DOI: 10.1016/j.biopha.2011.03.004


Related references

A 24-week treatment strategy with pegylated interferon/ribavirin in HIV/hepatitis C virus genotype 3-coinfected patients who achieved a rapid virologic response results in a high sustained virologic response rate. Clinical Infectious Diseases 58(1): 130-133, 2014

Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response. Hepatology 46(6): 1732-1740, 2007

Association between ribavirin plasma concentration and sustained virologic response in treatment of patients with genotype 1b chronic hepatitis C with pegylated interferon-α-2b and ribavirin. Zhonghua Gan Zang Bing Za Zhi 24(3): 175-180, 2016

Pegylated Interferon and Ribavirin Therapy for 24 Weeks Versus Shorter Duration for Patients with Hepatitis C Virus Genotype 2 and 3 Infection and Rapid Virologic Response: A Meta-Analysis. Gastroenterology 136(5): A-791, 2009

Optimal Duration of Pegylated Interferon Plus Ribavirin Therapy for Chronic Hepatitis C Genotype 3 Patients who do not Achieve Rapid Virological Response. Journal of Clinical and Experimental Hepatology 5(1): 2-7, 2015

A reduced dose of ribavirin does not influence the virologic response during pegylated interferon alpha-2b and ribavirin combination therapy in patients with genotype 1 chronic hepatitis C. Clinical and Molecular Hepatology 18(3): 272-278, 2012

Protein Pathway Biomarkers Predicting Sustained Virologic Response (Svr) to Pegylated Interferon (Peg-Ifn) and Ribavirin (Rbv) in Treatment-Naive Genotype 1 Patients With Chronic Hepatitis C (Ch-C). Gastroenterology 138(5): S-783, 2010

Rapid virological response tailors the duration of treatment in hepatitis C virus genotype 3 patients treated with pegylated interferon alfa-2a and ribavirin in Pakistan. International Journal of Infectious Diseases 17(11): E1017-E1021, 2013

Su1074 Meta-Analysis: Sustained Virologic Response (Svr) in Patients With Infection With Hepatitis C Virus Genotype 5 (Hcv-5) Versus Genotype 1 (Hcv-1) and Hcv Genotype 2/3 (Hcv -2/3) Treated With Interferon (Ifn) or Pegylated Interferon and Ribavirin (Peg Ifn+Rbv). Gastroenterology 146(5): S-981-S-982, 2014

24 weeks treatment with pegylated interferon alfa plus ribavirin may be possible in genotype 1 chronic hepatitis C patients with rapid virological response who have low pretreatment viremia. Korean Journal of Gastroenterology 56(1): 33-38, 2010

Pegylated interferon alpha-2b (Peg-IFN alpha-2b) affects early virologic response dose-dependently in patients with chronic hepatitis C genotype 1 during treatment with Peg-IFN alpha-2b plus ribavirin. Journal of Viral Hepatitis 16(8): 578-585, 2009

M1781 Rapid Virologic Response Predicts Sustained Virologic Response in Hepatitis C Patients Treated with Pegylated Interferon and Ribavirin Therapy. Gastroenterology 136(5): A-836-A-837, 2009

Rapid virological response in peripheral blood mononuclear cells with an increase of hepatitis C virus-specific interferon-gamma production predisposes to sustained virological response in patients with chronic hepatitis C genotype 1 undergoing treatment with pegylated-interferon alpha 2a plus ribavirin. Scandinavian Journal of Gastroenterology 45(2): 250-255, 2010

Comparison of early virologic response among patients with chronic hepatitis C infected with genotype non 2/3 treated with pegylated interferon alfa-2B and ribavirin in dependence with hepatic fibrosis stages. Przeglad Epidemiologiczny 60(4): 673-676, 2006

Prediction of early virologic response to treatment with 40kD pegylated -interferon alfa2a/ribavirin in patients with chronic hepatitis C. Gastroenterology 122(4 Suppl 1): A 626, 2002